We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Oxaliplatin versus mitomycin C in HIPEC for peritoneal metastasis from colorectal cancer: a systematic review and meta-analysis of comparative studies.
- Authors
Zhang, Xubing; Wu, Qingbin; Wei, Mingtian; Deng, Xiangbing; Gu, Chaoyang; Wang, Ziqiang
- Abstract
Background: Hyperthermic intraperitoneal perfusion chemotherapy (HIPEC) following cytoreductive surgery (CRS) has been applied for peritoneal metastasis (PM) from colorectal cancer (CRC). This study aimed to compare oxaliplatin (OX) with mitomycin C (MMC) in HIPEC for PM from CRC in surgical and survival outcomes. Methods: A systematic literature search was performed in PubMed and Ovid databases for studies comparing OX with MMC in HIPEC for PM from CRC. The last search was performed on June 21, 2020. Results: Eleven articles published between 2006 and 2020 with 2091 patients were included. When compared with MMC group, the OX group showed significantly higher rate of major complications (P = 0.006, OR = 1.57, 95% CI [1.14, 2.16], I2 = 0%). Besides, no significant difference was observed between the two groups for survival outcomes, regardless of 3-year overall survival (P = 0.98, OR = 1.00, 95% CI [0.83, 1.22], I2 = 0%), 3-year disease-free survival (P = 0.98, OR = 1.00, 95% CI [0.83, 1.22], I2 = 0%), or 5-year overall survival (P = 0.91, OR = 1.01, 95% CI [0.81, 1.26], I2 = 0%). Conclusion: OX and MMC could achieve comparable survival in HIPEC for PM from CRC. However, in consideration of the high incidence of major complication in OX group, MMC might be the safer one in clinical routines.
- Subjects
MITOMYCIN C; COLORECTAL cancer; HYPERTHERMIC intraperitoneal chemotherapy; META-analysis; OXALIPLATIN
- Publication
International Journal of Colorectal Disease, 2020, Vol 35, Issue 10, p1831
- ISSN
0179-1958
- Publication type
Article
- DOI
10.1007/s00384-020-03702-y